biote (BTMD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for May 13, 2025, to be held virtually for shareholders of record as of March 24, 2025.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with options to request paper or email copies.
Voting matters and shareholder proposals
Shareholders will vote to elect two Class III directors, Marc Beer and Bret Christensen, to serve until the 2028 annual meeting.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, is on the agenda.
The board recommends voting for all director nominees and for the auditor ratification proposal.
Additional business may be transacted as appropriate during the meeting.
Board of directors and corporate governance
Board recommends the election of two directors to serve three-year terms, subject to earlier death, resignation, or removal.
Latest events from biote
- 2025 revenue and margins fell, but investments aim for renewed growth in H2 2026.BTMD
Q4 202511 Mar 2026 - Q2 2024 saw procedure growth, strong margins, narrowed net loss, and reaffirmed 2024 guidance.BTMD
Q2 20242 Feb 2026 - Strong growth, tech-driven wellness expansion, and broad U.S. market opportunity highlighted.BTMD
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q3 revenue up 12.8% to $51.4M; guidance trimmed amid software and hurricane impacts.BTMD
Q3 202414 Jan 2026 - Q4 revenue up 9%, margin gains, and 2025 outlook projects further growth and profitability.BTMD
Q4 202426 Dec 2025 - Stockholders will vote on director elections and auditor ratification, with robust governance in place.BTMD
Proxy Filing2 Dec 2025 - Stockholders will vote on director elections and auditor ratification, with board-backed nominees.BTMD
Proxy Filing2 Dec 2025 - Q1 net income hit $15.8M on 4.7% revenue growth; 2025 outlook and restructuring reaffirmed.BTMD
Q1 202526 Nov 2025 - Q2 2025: Dietary supplement growth, higher margins, and restructuring drove improved profitability.BTMD
Q2 202523 Nov 2025